NORTHBROOK, Ill., July 20, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced that the U.S. Food and Drug Administration (FDA) has ...
The US Food and Drug Administration (FDA) has approved the use of the transplant drug tacrolimus (Prograf) for the prevention of organ rejection in adult and pediatric patients receiving lung ...
Kidney transplant recipients typically take the immunosuppressant drug tacrolimus to prevent rejection, and some patients experience large fluctuations in blood levels of tacrolimus even when the dose ...
Two drugs have been recalled because their capsules might be empty — and the consequences could be deadly. Astellas Pharma’s Prograf gets prescribed after heart, liver, kidney or lung transplants.
TOKYO, March 20 (Reuters) - Astellas Pharma Inc. <4503.T>, Japan's third-largest drug maker, said on Tuesday that U.S. authorities have said they could not yet approve the simultaneous use of its ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved the immunosuppressant drug tacrolimus to prevent rejection in adult and pediatric patients ...
(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays) By ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results